Table 2 Characteristics of patients receiving or not receiving baricitinib in the unmatched and matched study population from the Albacete Hospital (Spain).

IMV, invasive mechanical ventilation. All data are means (SD) or number of participants (%).

Baricitinib group (n = 46)Control group (n = 376)PS matched control group (n = 46)
Age80.9 (5.8)82.7 (6.3)80.6 (6.3)
Male sex30 (65.2)201 (53.5)30 (65.2)
Interval between symptom onset and
admission
7.4 (5.2)7.3 (4.9)7.3 (5.1)
Coexisting conditions
  Hypertension34 (73.9)296 (78.7)35 (76.1)
  Cardiovascular disease18 (39.1)167 (44.4)15 (32.6)
  Solid cancer2 (4.3)20 (5.3)1 (2.2)
  Diabetes21 (45.7)139 (37.0)14 (30.4)
  COPD11 (23.9)84 (22.3)12 (26.1)
  Chronic kidney failure5 (10.9)64 (17.0)6 (13.0)
Charlson comorbidity index2.9 (2.3)2.0 (1.9)3.2 (2.8)
Medications at baseline
  ACE inhibitor or ARB24 (52.2)196 (52.3)26 (56.5)
  Direct oral anticoagulant or warfarin8 (17.4)65 (17.3)4 (8.7)
  Antiaggregants14 (30.4)121 (32.2)15 (32.6)
  Statins23 (50.0)158 (42.0)21 (45.7)
  Insulin9 (19.6)42 (11.2)4 (4.3)
  Oral hypoglycemic agents15 (32.6)109 (29.0)13 (28.3)
  Antidepressants10 (21.7)123 (32.7)11 (23.9)
  Inhaled therapy for COPD12 (26.1)95 (25.3)15 (32.6)
Baseline PaO2/FiO2284 (109)280 (107)282 (96)
Baseline laboratory tests
  D-dimer (μg/liter)6944 (18,052)6182 (26,894)5443 (16,872)
  Lactate dehydrogenase (U/liter)387 (136)372 (288)370 (166)
  C-reactive protein (mg/liter)147.2 (98.6)137.6 (118.0)141.8 (145.8)
  Ferritin (ng/ml)1357 (1094)**878 (975)**1039 (927)
  Leucocyte count (per μl)9414 (4790)8986 (4711)7690 (3675)
  Lymphocyte count (per μl)987 (905)967 (777)934 (517)
  Hemoglobin (g/dl)13.7 (2.1)13.2 (2.1)13.7 (3.2)
  Fibrinogen (mg/dl)395 (78)378 (175)375 (70)
  Creatinine (mg/dl)1.2 (0.5)1.3 (0.91)1.1 (0.5)
  AST (U/liter)35.5 (23.4)41.4 (40.3)40 (46)
  Gamma-glutamyltransferase (U/liter)63.3 (49.5)54.2 (74.3)65.5 (119.2)
  ALT (U/liter)33.8 (25.3)30.8 (57.3)31.0 (25.5)
ALT (U/liter) after treatment, at discharge47.5 (45.8)
ALT > 2× ULN after treatment, at discharge5 (9.1)
ALT > 3× ULN after treatment, at discharge3 (5.5)
Chest x-ray
  Interstitial pattern46 (100)345 (93.0)44 (95.7)
  Opacities38 (82.6)*233 (63.7)*32 (69.6)
  Severity score3.4 (2.1)**2.2 (2.2)**2.4 (2.1)
Concomitant treatment
  Hydroxychloroquine45 (97.8)*321 (85.4)*46 (100)
  Antibiotics46 (100)365 (97.1)45 (97.8)
  Lopinavir/ritonavir39 (84.8)288 (76.8)42 (91.3)
  LMWH (enoxaparin)46 (100)**322 (85.6)**46 (100)
  Glucocorticoids44 (95.7)***266 (70.7)***42 (91.3)
  Anakinra18 (39.1)***29 (7.7)***10 (21.7)
Primary outcome (mortality or IMV)9 (19.6)**157 (41.8)**16 (34.8)

*P < 0.05

**P < 0.01

***P < 0.001